Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 14:12:651415.
doi: 10.3389/fphar.2021.651415. eCollection 2021.

Novel and Emerging Therapies for Inflammatory Bowel Disease

Badr Al-Bawardy  1 , Raina Shivashankar  2 , Deborah D Proctor  1
Affiliations
Review

Novel and Emerging Therapies for Inflammatory Bowel Disease

Badr Al-Bawardy et al. Front Pharmacol. .

Abstract

Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic manifestations. Despite the availability of current biologics, such as anti-tumor necrosis factor (anti-TNF), anti-integrins, anti-interleukins and small molecules such as tofacitinib, the rates of primary and secondary treatment failure remain high in IBD. This highlights the importance of continued development of new therapeutic targets and modifications of existing ones to improve the treatment response rates and to also improve the safety profile and tolerability of these medications. In this review we will discuss novel treatment target agents including selective janus kinase (JAK) inhibitors, anti-interleukin (IL) (IL-12/IL-23), leukocyte trafficking/migrating inhibitors (such as sphingosine-1-phosphate receptor modulator) and other small molecules currently in development.

Keywords: biologic; emerging therapy; inflammatory bowel disease; novel therapy; small molecule.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Almon E., Shaaltiel Y., Sbeit W., Fich A., Schwartz D., Waterman M., et al. (2020). Novel orally administered recombinant anti-TNF alpha fusion protein for the treatment of ulcerative colitis: results from a phase 2a clinical trial. J. Clin. Gastroenterol. 55(2). 134–140. 10.1097/MCG.0000000000001314 - DOI - PMC - PubMed
    1. Anderson C. A., Boucher G., Lees C. W., Franke A., D'Amato M., Taylor K. D., et al. (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43, 246–252. 10.1038/ng.764 - DOI - PMC - PubMed
    1. Atreya R., Bloom S., Scaldaferri F., Gerardi V., Admyre C., Karlsson Å., et al. (2016). Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis. Eccojc 10, 1294–1302. 10.1093/ecco-jcc/jjw103 - DOI - PMC - PubMed
    1. Atreya R., Peyrin-Biroulet L., Klymenko A., Augustyn M., Bakulin I., Slankamenac D., et al. (2020). Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol. Hepatol. 5, 1063–1075. 10.1016/s2468-1253(20)30301-0 - DOI - PubMed
    1. Authors (2019). A SPECIAL MEETING review EDITION: highlights in inflammatory bowel disease from the 14th congress of ECCO: a review of selected Presentations from the 14th congress of the European Crohn's and colitis organisation (ECCO) * March 6-9, 2019 * copenhagen, DenmarkSpecial reporting on:* VARSITY: a double-blind, double-dummy, randomized controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis* analyses of data from the VISIBLE 1 and 2 trials: vedolizumab in patients with ulcerative colitis or Crohn's disease* improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in Adults with moderately to severely active ulcerative colitis: data from the U-achieve study* long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study* pediatric Crohn's disease adalimumab level-based optimization treatment (PAILOT) randomized controlled trial* maintenance treatment with mirikizumab, a P19-directed IL-23 antibody: 52-week results in patients with moderately to severely active ulcerative colitis* real-world effectiveness and safety of vedolizumab and anti-TNF therapy in biologic-naive patients with ulcerative colitis or Crohn's disease: results from the EVOLVE study* A randomized, multicenter, double-blind, placebo-controlled study of a targeted-release oral cyclosporine formulation in the treatment of mild to moderate ulcerative colitis: efficacy results* real-world analyses of patients with IBD treated with VedolizumabPLUS meeting Abstract Summaries with Expert commentary by: edward V. Loftus Jr, MDProfessor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota. Gastroenterol. Hepatol. (N Y) 15, 1–24. - PMC - PubMed

LinkOut - more resources